There is no cost to you for this study (study drug, the labs, the visits), and you will be reimbursed $35.00 per completed study visit for transport costs. This study is a treatment for PSA. It's a Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib (ABT-494) to Placebo and to Humira in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD). The study can last a little over 4 years: 35-day screening period, 2 drug-testing periods, a 30-day follow-up call or visit, and a 70-day follow-up call.
Indication: PSA - Psoriatic Arthrtis
Protocol number: M15-572
Possible Stipend: $ 1300
Check back soon for more features!